EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Lexicon Pharmaceuticals's enterprise value is $357.10 Mil.
Lexicon Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-163.46 Mil. Therefore, Lexicon Pharmaceuticals's EV-to-EBITDA for today is -2.18.
The historical rank and industry rank for Lexicon Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
LXRX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -558.75 Med: -6.97 Max: 347.24
Current: -2.18
During the past 13 years, the highest EV-to-EBITDA of Lexicon Pharmaceuticals was 347.24. The lowest was -558.75. And the median was -6.97.
LXRX's EV-to-EBITDA is ranked worse than 100% of 472
companies
in the Biotechnology industry
Industry Median: 9.005
vs LXRX: -2.18
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-23), Lexicon Pharmaceuticals's stock price is $1.61.
Lexicon Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.800. Therefore, Lexicon Pharmaceuticals's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Lexicon Pharmaceuticals EV-to-EBITDA Historical Data
The historical data trend for Lexicon Pharmaceuticals's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Lexicon Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lexicon Pharmaceuticals EV-to-EBITDA Distribution
For the Biotechnology industry and Healthcare sector, Lexicon Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Lexicon Pharmaceuticals's EV-to-EBITDA falls into.
Lexicon Pharmaceuticals EV-to-EBITDA Calculation
Lexicon Pharmaceuticals's EV-to-EBITDA for today is calculated as:
Lexicon Pharmaceuticals's current Enterprise Value is $357.10 Mil.
Lexicon Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-163.46 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Lexicon Pharmaceuticals's PE Ratio for today is calculated as:
Lexicon Pharmaceuticals's share price for today is $1.61.
Lexicon Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.800.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Lexicon Pharmaceuticals EV-to-EBITDA Related Terms
Thank you for viewing the detailed overview of Lexicon Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Lexicon Pharmaceuticals (Lexicon Pharmaceuticals) Business Description
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drugs candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LXRX has been successfully added to your 